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Background: EBV-associated T/NK-cell lymphoproliferative diseases (TNKLPD) is a rare spectrum of disease that occurs
more commonly in Asia, and Central and South America. It commonly affects children and young adults and is an
aggressive disease that is poorly understood with no known biologic markers that can predict prognosis. The systemic
form of TNKLPD includes chronic active EBV infection of T/NK type, aggressive NK cell leukemia and systemic
EBV + T-cell lymphoproliferative disease of childhood.
Methods: In this study, we analyse the clinicopathologic and genetic features of 22 cases of systemic TNKLPD in
non-immunocompromised patients, including chronic active EBV infection of T/NK cell type and systemic EBV +
T-cell lymphoproliferative disease of childhood. We also performed gene expression profiling in a subset of cases
to identify markers that may be of prognostic relevance and validated our results using immunohistochemistry.
Results: The median age is 14.9 years and two of our 22 cases occurring in patients older than 30 years. Fifteen of 17
cases (88%) with adequate data were of T-cell origin. Eleven of 22 cases revealed polymorphic cellular infiltrate
(P-group) while the rest showed monomorphic lymphoid infiltrate (M-group). We found a significant difference in
survival between P-group vs M-group patients with median survival not yet reached in P-group, and 1 month in
M-group (p = 0.0001), suggesting a role for morphology in predicting patient outcome. We also performed gene
expression profiling in a subset of patients and compared the genes differentially expressed between P-group and
M-group cases to identify markers of prognostic value. We identified cyclin E2 gene and protein to be differentially
expressed between patients with good outcome (P-group, median expression 8%) and poor outcome (M-group,
median expression 42%) (p = 0.0005). In addition, the upregulation of cyclin E2 protein in M-group cases correlated
with a higher Ki67 proliferation rate (Pearson correlation r = 0.73, p = 0.0006) detected by immunohistochemistry. High
cyclin E2 expression was also significantly associated with shorter survival (p = 0.0002).
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Conclusion: Our data suggests the potential role of monomorphic morphology, high cyclin E2 and Ki67 expression as
adverse prognostic factors for TNKLPD.
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PrognosisBackground
The term EBV-associated T/NK-cell lymphoproliferative
disorders (TNKLPD) encompasses a spectrum of disease
entities in non-immunocompromised patients charac-
terised by an Epstein-Barr virus (EBV)-infected, cytotoxic
T or NK-cell proliferation that is polyclonal or monoclo-
nal. The systemic form of TNKLPD includes chronic ac-
tive EBV infection of T/NK-cell type (CAEBV), aggressive
NK cell leukemia (ANKL) and systemic EBV-positive T-
cell lymphoproliferative disease of childhood (STLPDC)
[1-4]. TNKLPD is rare in the Western population and
occurs with increased frequency in Asians, Native
Americans from Central and South America and Mexico
[1,2] Morphologically, it is characterized by a wide-
ranging cytological appearance from reactive appear-
ance to overt leukemia/lymphoma [5-7]. The diagnosis
of TNKLPD can be challenging because cytologic fea-
tures may be deceptively benign despite the frequently
aggressive clinical behaviour.
Historically, the terminology and classification of
TNKLPD have been problematic as this process has
been described under a variety of terms including: fulmin-
ant EBV + T-cell lymphoproliferative disease (LPD) of
childhood [8], fatal infectious mononucleosis; fulminant
hemophagocytic syndrome in children in Taiwan [9], fatal
EBV-associated hemophagocytic syndrome in Japan [10]
and severe CAEBV [11]. However, recent efforts have
been made to achieve international consensus on the no-
menclature and classification of TNKLPD and it is now
recognized that most of the EBV-associated T/NK LPD
in immunocompetent children and young adults with
systemic presentation belong to the same spectrum of
disease, including CAEBV and STLPDC. A consensus
meeting was held at the National Institute of Health
(NIH) in 2008 and it was recommended that the term
CAEBV should be applied to systemic LPDs that are not
frank lymphomas and that arise during primary infection
and persist for over 6 months. On the other hand, the
term ‘systemic EBV-positive T-cell LPD’, as adopted by
the WHO classification, is the preferred pathologic desig-
nation over CAEBV for those cases that are clonal with an
aggressive clinical course and require aggressive treatment
[12]. A clinicopathological categorization of TNKLPD was
proposed by Ohshima et al. in 2008 [13]. According to the
proposal, EBV-associated T/NK LPD in children can becategorised into 4 groups (A1, A2, A3 and B) based on
morphology of the infiltrate, clonality and clinical pres-
entation. A consensus report following the 4th Asian
Hematopathology Workshop on the classification and ter-
minology of TNKLPD was also recently published [14]. In
this report, TNKLPD can be divided into systemic and cu-
taneous forms (see Additional file 1, for a summary of the
proposed classifications of TNKLPD). The systemic form
includes CAEBV-T/NK, ANKL and STLPDC.
In this study, we analysed the clinicopathologic and gen-
etic features of 22 cases of systemic form of TNKLPD in
Singapore and Japan using the criteria recommended by
WHO and NIH in 2008, including CAEBV and STLPDC.
We found that patients with polymorphic infiltrate (P-
group) have a significantly better outcome than cases with
monomorphic infiltrate (M-group). We then performed,
for the first time, gene expression profiling (GEP) in a sub-
set of patients and compared the gene signature between
P-group and M-group patients with good and poor out-
come, respectively, in order to identifying targets that may
be important in predicting outcome.
Methods
Case selection and definition
Patients with a diagnosis of EBV-associated T/NK-cell
lymphoproliferative disorder without known underlying
immune deficiency were identified from the archives of
the Department of Pathology, National University Hos-
pital (NUH), and Kurume University, from 2003 to 2013.
Cases were reviewed, additional immunohistochemistry
and in-situ hybridization for EBV-encoded small RNA
(EBER) were performed and the cases were classified ac-
cording to the 2008 WHO lymphoma classification and
nomenclature proposed following the NIH consensus re-
port in 2008 (Table 1) [12]. The determination of T vs NK
cell lineage is based on the TCRG gene clonality and pro-
tein expression of TCRαβ and TCRγδ. Extranodal nasal-
type NK/T-cell lymphoma cases were excluded. A total of
22 cases with adequate material for workup and fulfilled
the diagnostic criteria were identified and included
CAEBV of T/NK type, and systemic EBV-associated T-
cell LPD of childhood. The clinical history, previous biop-
sies and laboratory results were reviewed for evidence of
hemophagocytic lymphohistiocytosis (HLH). Hemophago-
cytic lymphohistiocytosis (HLH) is defined by at least five
Table 1 Pathologic and genetic features and classification of EBV + T/NK-cell lymphoproliferative disease
No Diagnosis* Ohshima category** Histo CD4 CD8 CD56 TCR αβ TCR γδ TCR PCR Cell of origin BM karyotype
1 CAEBV A1 P - - - - - PC TCR silent vs NK N
2 CAEBV A1 P - + - + - PC T N
3 CAEBV A1 P - + + - - PC TCR silent vs NK N
4 STLPDC A2 P - + - + - MC T N
5 STLPDC A2 P - + - - - MC T N
6 STLPDC A2 P - + - - - MC T N
7 STLPDC A2 P + - + Focal + - MC T N
8 CAEBV vs STLPDC A1 or A2 P NA NA + NA NA NA NA NA
9 CAEBV vs STLPDC A1 or A2 P - + - NA NA NA NA NA
10 CAEBV vs STLPDC A1 or A2 P + + - NA NA NA NA NA
11 CAEBV vs STLPDC A1 or A2 P NA NA - NA NA NA NA NA
12 STLPDC A3 M - + + Focal + - MC T Abn
13 STLPDC A3 M - + - + - MC T N
14 STLPDC B M - + + + - MC T Abn
15 STLPDC B M - + - - - MC T Abn
16 STLPDC B M + - - Focal + - PC favour T Abn
17 STLPDC B M - + - + - MC T N
18 STLPDC B M - + - + - MC T Mosaic
19 STLPDC B M - + - + - NA T N
20 STLPDC B M + - - + NA PC T Abn
21 STLPDC B M - - - NA NA NA‡ NA NA
22 favour STLPDC A3 or B M - - + + - NA T NA
Abbreviations: Histo histology, M monomorphic, P polymorphic, TCR clonality for T-Cell Receptor Gamma gene by PCR, MC monoclonal, PC polyclonal, Abn abnormal,
N normal, NA not available, OS overall survival, BM bone marrow, CAEBV chronic active EBV infection of T-NK type, STLPDC systemic EBV + T cell lymphoproliferative
disorder of childhood, EBV + TLPD EBV-positive T cell lymphoproliferative disorder.
‡EBV terminal repeats analysis revealed monoclonality.
*Based on WHO classification and recommendation from NIH consensus meeting in 2008 [12].
**Based on categorization of EBV + T/NK lymphoproliferative disorders in children by Ohshima et al. [13].
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topenia, hypertriglyceridemia, and/or hypofibrinogen-
emia, hemophagocytosis, low/absent NK-cell-activity,
hyperferritinemia, and high-soluble interleukin-2-receptor
levels [15].
Based on the WHO classification and NIH recommen-
dation [1,12], the term ‘CAEBV’ is applied to systemic
LPDs that are not frank lymphomas and that arise during
primary infection and persist for over 6 months. The term
‘systemic EBV-positive T-cell LPD’, as adopted by the
WHO classification, is used for those cases that are mono-
clonal. We also categorized the cases based on the criteria
proposed by Ohshima et al. [13] (ie. morphology, clonality
and clinical presentation) into the following (i) category
A1, polymorphic and polyclonal LPD; (ii) category A2,
polymorphic and monoclonal LPD; (iii) category A3,
monomorphic and monoclonal LPD; and (iv) category
B, monomorphic and monoclonal LPD with fulminant
course (Table 1). We considered the presence of an ab-
normal karyotype and/or monoclonal TCRG gene re-
arrangement as indicative of a clonal proliferation [14].Fulminant course is defined as rapid clinical progression
within 1 or 2 months [2]. Follow up data was collected.
Four of the 22 cases of TNKLPD with adequate forma-
lin fixed paraffin embedded (FFPE) tissue and good qual-
ity RNA were selected for GEP (cases 5, 7, 16, 17, see
Table 2). The FFPE tissues used for GEP included lymph
node and skin biopsies. FFPE control tissues from nor-
mal skin and lymph node were also included. This study
is approved by the Domain Specific Review Board of the
National Healthcare Group, Singapore.
RNA extraction from FFPE for gene expression profiling
Total RNA from human FFPE tissues were isolated using
High Pure RNA Paraffin Kit (Roche Applied Science,
Mannheim Germany) according to the manufacturer’s
recommendations. To achieve higher recovery of RNA,
10 μm FFPE sections were deparaffinized with 100% xy-
lene followed by 100% ethanol. The dried tissues were
then subjected to proteinase K digestion and remaining
steps were performed as per the manufacturer’s protocol.
Concentration and purity of total RNA samples were
Table 2 Clinical, survival and treatment data of EBV + TNK-cell lymphoproliferative disease
No Ohshima category* Histo Sex Ethnicity Age (yrs) Tissue type GEP HLH Treatment Follow up OS (mth)
1 A1 P M Indonesian 3.4 BM No + HLH -P Alive 55
2 A1 P M Chinese 13.1 BM No + HLH-P, AHCT Dead (AHCT complications) 48
3 A1 P M Vietnamese 24.8 BM No + Chemo Alive 6
4 A2 P F Chinese 5.3 BM No + HLH-P, AHCT Alive 64
5 A2 P M Chinese 1.4 Skin Yes + HLH-P , AHCT Alive (graft rejection) 95
6 A2 P F Indonesian 6.1 BM No + HLH-P Alive 31
7 A2 P M Chinese 16.7 LN Yes - Steroids, AHCT Dead 14
8 A1 or A2 P M Japanese 4 liver No + AHCT Alive 94.4
9 A1 or A2 P F Japanese 19 BM No - AHCT Alive 9.2
10 A1 or A2 P F Japanese 19 BM No + Chemo Alive 32.5
11 A1 or A2 P F Japanese 39 Skin No - Chemo Dead 21.8
12 A3 M F Vietnamese 16.4 BM No + HLH-P Dead 0.4
13 A3 M F Chinese 4.8 BM No + HLH-P Alive 21
14 B M M Indonesian 13.3 BM No + HLH -P Dead 0.83
15 B M M Indonesian 20.9 BM No + HLH -P Dead 2
16 B M F Chinese 9.5 LN Yes + Supportive Dead 1
17 B M M Chinese 18.7 LN Yes + HLH -P Dead 1.16
18 B M M Vietnamese 1 BM No + HLH-P NA NA
19 B M M Filipino 7.6 BM No + HLH-P Dead 1
20 B M F Chinese 19.3 BM No + HLH-P Dead 0.1
21 B M F Japanese 48 BM No + Chemo, AHCT Dead 2.2
22 A3 or B M M Others 18.3 BM No NA Supportive Dead 0.7
Abbreviations: M male, F female, Histo histology, P polymorphic, M monomorphic, HLH-P 2004 Histiocytic Lymphohistiocytosis protocol, AHCT Allogeneic
hematopoietic cell transplant, + present, − absent, TCR Clonality for TCRG gene, R rearranged, NR not rearranged, NA not available, OS overall survival, LN lymph node,
BM bone marrow, Chemo chemotherapy. *Categorization of EBV-associated T/NK LPD in children proposed by Ohshima et al. [13].
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eter (NanoDrop Technologies Inc, Wilmington, DE).
RNA integrity was assessed with the Agilent 2100 Bioa-
nalyzer (Agilent Technologies, Palo Alto, CA) and the
RNA 6000 LabChip kit (Agilent Technologies).
Gene expression profiling and analysis
We conducted a genome-wide gene expression profiling
(GEP) on TNKLPD and normal control FFPE samples
using the Illumina WG-DASL (Whole Genome cDNA-
mediated Annealing, Selection, and Ligation) (Illumina,
Inc., San Diego) [16,17]. Briefly, 250 ng of total RNA
from each sample were converted to biotinylated cDNA
using the Illumina® TotalPrep RNA Amplification Kit
(Ambion, Inc., Austin, TX, USA) according to the manu-
facturer’s recommendations. The cDNA targets were hy-
bridized to HumanRef-8 Expression BeadChip arrays
(Illumina, Inc., San Diego), which contain 24526 probes,
for 16 hours before being washed and stained with
streptavidin-Cy3 according to the manufacturer’s proto-
col. The beadchips were scanned and quantitated using
Illumina’s Bead-Station 500GX Genetic Analysis Systems
scanner. The raw signals extracted were normalizedusing a linear calibration method, as described in our
previous paper [18]. Analysis of the data was done by
R/Bioconductor.
Since we found a significantly poorer survival in pa-
tients with polymorphic infiltrate (P-group) vs patients
with monomorphic infiltrate (M-group), we compared
genes that are differentially expressed between P-group
and M-group to identify genes that are of prognostic
value. Significance analysis of microarrays (SAM) [19]
was not appropriate due to the small sample size and we
selected the genes with more than 4-fold change for
comparison between the two groups with good and poor
outcome.
Immunohistochemistry (IHC)
In order to validate the expression of cyclin E2 and Ki67
in the CD3-positive tumor cells and not the reactive popu-
lation, we performed the following double stains CD3/
cyclin E2 and CD3/Ki67 on four-μm sections of TNKLPD
samples [including bone marrow (BM), skin and
lymph node (LN) biopsies] using the conditions listed
in Additional file 2. Appropriate positive tissue controls
were used. The stains were performed using Leica
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sion for the antibodies was manually scored as a percent-
age of the CD3-positive tumor cell population by one of
the authors (NSB), without knowledge of the clinicopatho-
logic and GEP data. Since there is no well-established cut-
off criteria for high cyclinE2 expression in the literature,
we determined the median value of cyclinE2 expression in
our 22 cases and defined high cyclinE2 expression as equal
or greater than the median expression. The median ex-
pression of cyclinE2 was determined as 15% in our cases
and high cyclinE2 expression is defined as 15% or more
expression in the CD3-positive tumor cell population.
Results
Clinical and laboratory findings
The age of the patients ranged from 1 to 48 years old
with median age at the time of diagnosis of 14.9 years
(Table 2). Two of our cases occurred in patients older thanFigure 1 Morphology and phenotype of TNKLPD. Case with polymorph
with minimal atypia, histiocytes and eosinophils (A, H&E, original magnificatio
cells with irregular nuclei (B, H&E, original magnification 600×). Expression of c
stain, EBER stains nucleus brown and TIA1 stains cytoplasmic granules red
hybridization in CD3-positive tumor cells (D, EBER/CD3 double stain, EBER
original magnification 1000×). Positive expression for CD56 (E, CD56, orig
600×). All photographs were taken with a DP20 Olympus camera (Olympus, T
acquired using DP Controller 2002 (Olympus) and processed using Adobe Ph30 years of age (case 11 and 21) similar to previous obser-
vations that this disease can occasionally affect adults
[4,13,14]. There were 12 males and 10 females. All the
cases presented with fever. Hepatomegaly and/or spleno-
megaly were present in 21 of 22 patients. Nine of 18 pa-
tients with adequate data had lymphadenopathy and 21
out of 22 had cytopenias. 18 out of 21 cases fulfilled the
criteria of HLH. Polymerase chain reaction (PCR) for EBV
was detected in the blood of all 17 cases with adequate
data.
Pathologic features
Microscopically, the biopsies from BM, LN and skin
showed a broad spectrum of appearance ranging from
polymorphic cellular infiltrate (Figure 1A) composed of
abundant reactive cells, to overtly malignant monomorph-
ous lymphoid proliferation (Figure 1B). Hemophagocytosis
is evident in the majority of cases. Eleven of 22 casesic infiltrate composed of mixed population of small lymphoid cells
n 600×). Monomorphic infiltrate consisting of large malignant lymphoid
ytotoxic marker TIA1 in EBER-positive tumour cells (C, EBER/TIA1 double
, original magnification 1000×). Positive expression for EBER in situ
stains nucleus brown and CD3 stains cell membrane/cytoplasm red,
inal magnification 600×) and TCRbeta (F, TCRB, original magnification
okyo, Japan) using an Olympus BX41 microscope (Olympus). Images were
otoshop version 5.5 (Adobe Systems, San Jose, CA, USA).
Figure 2 Statistically significant difference in survival between
P-group (A1 and A2 subtypes) and -M-group (A3 and B subtypes)
cases.
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showed monomorphic lymphoid infiltrate (Table 1).
Phenotypically, all cases revealed a CD3+ cytotoxic
T/NK-cell lymphoid infiltrate which expresses EBER by
in-situ hybridization (Figures 1C and D). Of the 20 cases
tested, 13 were CD4-/CD8+ and 3 were CD4-/CD8-.
Another three were CD4+/CD8- and one case was CD4+
/CD8+. Expression of CD56 was present in 6 cases
(Figure 1E). TCRαβ immunoreactivity was seen in 12
of 17 cases (Figure 1F) tested. All cases studied were nega-
tive for TCRγδ protein. Monoclonal T-cell receptor
gamma gene rearrangement was detected in 10 out of
15 patients, of which 4 cases revealed a polymorphic
proliferation. Bone marrow cytogenetics was performed
in 16 cases, of which 5 revealed abnormal karyotypes.
With regards to cell lineage, 15 of the 17 cases (88%)
with adequate workup were of T cell lineage; 10 of these
15 cases had clonal rearrangement of TCRG gene by PCR,
the remaining 5 cases showed positive expression for
TCRαβ. Two cases (1 and 3) were negative for TCRαβ
and TCRγδ, and TCRG gene was polyclonal. These 2
cases may represent either a TCR-silent or NK phenotype
(Table 1).
Categorization of TNKLPD, treatment and clinical
outcome
The diagnosis of the cases based on WHO and NIH pro-
posed nomenclature [12] as well as the corresponding
categorization as proposed by Ohshima et al. [13] are pro-
vided in Table 1. Three cases were classified as CAEBV
and 15 were STLPDC. The remaining 4 cases were diffi-
cult to classify accurately because of lack of clonality data.
All the CAEBV cases had polymorphic infiltrate and are
polyclonal by definition (Ohshima type A1). Of the 15
STLPDC, 4 cases had polymorphic and monoclonal infil-
trate, corresponding to Ohshima type A2. The remaining
11 STLPDC cases showed monomorphic proliferation.
Case 12 was categorised as Ohshima type A3 although the
patient died 0.4 month after diagnosis because she pre-
sented with symptoms for 2 years prior to diagnosis.
There were no cases of aggressive NK cell leukemia and
all our cases with aggressive clinical course were of T cell
origin.
Follow up was available in 21 cases with median of
11.6 months (ranged from 3 days to 8.9 years). The over-
all median survival was 21.8 months. Of the 18 cases
that could be classified, the median survival for STLPDC
was 2 months compared to median survival not yet
reached for CAEBV. However, this difference was not
significant and may be related to small sample size (p =
0.0668).
Interestingly, cases with polymorphic infiltrate (P-group)
and those with monomorphic infiltrate (M-group) showed
a statistically significant difference in survival with mediansurvival not yet reached in P-group and 1 month in M-
group (p = 0.0001) (Figure 2). We did not find any signifi-
cant difference in survival between cases with polyclonal
and monoclonal lymphoid infiltrate, although this may
again be due to small sample size.
Five of 11 patients in P-group were treated with 2004
HLH protocol, a chemo-immunotherapy which includes
etoposide, dexamethasone, cyclosporine A upfront and,
in selected patients, intrathecal therapy with methotrex-
ate and corticosteroids [15] (Table 2). Six P-group cases
also received allogeneic hematopoietic cell transplant
(AHCT), of which one died of disease and one died from
AHCT related complications. The other 4 patients who
received AHCT remained alive although one patient had
graft rejection. Overall, 8 out of 11 P-group patients
remained alive. In contrast, 9 of 10 patients in M-group
with follow up data died of disease and only one patient
remained alive at 21 months of follow up. Eight of
11 M-group patients were treated with 2004 HLH proto-
col while the other 2 received supportive management.
Except for one M-group case who received chemother-
apy and AHCT, none of the other cases received AHCT
because of the rapid clinical progression.
Cyclin E2 expression is associated with high proliferation
and poor outcome in TNKLPD
Of the 4 cases that were profiled, 2 cases belonged to P-
group (polymorphic infiltrate) and the other 2 were in M-
group (monomorphic infiltrate). Since the 2 groups
showed significant difference in survival, we compared the
genes differentially expressed between the two groups in
order to identify targets that are associated with poor out-
come. A total of 74 genes showed a 4-fold difference in
expression between the 2 groups, of which 34 were up-
regulated (including CCNE2/cyclin E2) and 40 were
downregulated in the group with shorter survival
(Figure 3).
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immunohistochemistry on a few selected genes of inter-
est and we found that there is a significant overexpres-
sion of cyclin E2 protein in M-group patients compared
to P-group (median expression of 42% compared with
8%, p = 0.0005) (Figure 4A, Table 3). There is also a sta-
tistically significant difference in survival between pa-
tients with low vs high cyclin E2 expression (median
survival not yet reached vs 1.16 months, p = 0.0002)Figure 3 Differentially expressed genes between P-group and M-grou(Figure 4B) suggesting a potential role of cyclin E2 as an
adverse prognostic marker in TNKLPD. Interestingly,
only one case in P-group (case 11) had a high cyclin E2
expression and this patient also died of disease less than
2 years after diagnosis. Since cyclin E2 has an important
role in cell cycle progression, we also performed Ki-67/
CD3 double stain to determine if the upregulation of
cyclin E2 in M-group of TNKLPD correlated with a
higher proliferation rate in this group. Indeed, we foundp patients with TNKLPD.
Figure 4 Cyclin E2 expression was associated with high proliferation rate and poor outcome in TNKLPD. Significantly higher cyclin E2
expression was present in M-group compared to P-group patients (A, median expression of 42% compared with 8%, p = 0.0005). Patients with
high tumor cyclin E2 expression of 15% or greater had statistically significant shorter survival compared with those with low cyclin E2 expression
less than 15% (B, p = 0.0002). High cyclin E2 expression is highly correlated with high Ki-67 proliferation rate (C, spearman r = 0.73, p = 0.0006).
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spearman correlation r = 0.73, p = 0.0006 (Figure 4C,
Table 3, Figure 5). The IHC of other selected genes were
not included because of technical difficulty in performing
double stains in TNKLPD tissue samples which included
mostly bone marrow biopsy sections.
Discussion
Chronic active EBV infection of T/NK type (CAEBV-T/
NK), aggressive NK cell leukemia (ANKL) in children and
systemic EBV + T-cell lymphoproliferative disorders (LPD)
of childhood are a group of systemic EBV-associated T/
NK cell LPD that is prevalent in children and young adults
in Asia, Native Americans in Mexico and South America
[12,20]. Although rare, this is an important group of dis-
ease to study because very little is known about the dis-
ease pathogenesis, and they are often aggressive in
behavior with no effective treatment. Furthermore, bio-
logic markers useful in predicting patient outcome have
also not been identified. This is attributed to the rarity
of the disease and limited availability of tissue because
most of the tissue samples from such patients are bonemarrow biopsies containing scanty amount of tumor of
suboptimal quality secondary to decalcification that is re-
quired for the processing of bone marrow tissue samples.
In this study, we describe 22 cases of TNKLPD in
Singapore and Japan which includes CAEBV-T/NK and
systemic EBV + T-cell LPD in childhood. Although
TNKLPD affects mainly children and young adults, two of
our cases occurred in patients older than 30 years, similar
to observations from previous studies that this disease can
occasionally occur in older adults [4,13,14]. There were no
aggressive NK cell leukemia (ANKL) and all our TNKLPD
with fulminant clinical course (Ohshima B subtype) were
of T cell origin and classified as systemic EBV-positive T
cell LPD of childhood. The lack of systemic fulminant
TNKLPD disease of NK origin may be due to more com-
prehensive testing for TCR clonality in combination with
immunohistochemistry for the expression of TCRαβ and
TCRγδ. Since antibodies for TCRαβ and TCRγδ for for-
malin fixed paraffin sections are only available in the re-
cent years, it is possible that some of the ANKL diagnosed
in the past may actually be of T cell origin due to limited
T cell assessment.
Table 3 Immunohistochemical expression of cyclin E2 and Ki67 in CD3-positive tumor population of TNKLPD
Case No. Diagnosis Ohshima category Histology Cyclin E2 (%) Ki67 (%) Follow up OS (mth)
1 CAEBV A1 P 3 5 Alive 55
2 CAEBV A1 P 8 NA Dead (AHCT complications) 48
3 CAEBV A1 P 0 0 Alive 6
4 STLPDC A2 P 8 6 Alive 64
5 STLPDC A2 P 1 1 Alive cgraft rejection) 95
6 STLPDC A2 P 5 12 Alive 31
7 STLPDC A2 P 8 3 Dead 14
8 CAEBV vs STLPDC A1 or A2 P 8 1 Alive 94.4
9 CAEBV vs STLPDC A1 or A2 P 7 8 Alive 9.2
10 CAEBV vs STLPDC A1 or A2 P 8 9 Alive 32.5
11 CAEBV vs STLPDC A1 or A2 P 44 4 Dead 21.8
12 STLPDC A3 M 90 NA Dead 0.4
13 STLPDC A3 M 70 75 Alive 21
14 STLPDC B M 49 44 Dead 0.83
15 STLPDC B M 35 NA Dead 2
16 STLPDC B M 70 70 Dead 1
17 STLPDC B M 15 60 Dead 1.16
18 STLPDC B M 30 82 NA NA
19 STLPDC B M 35 90 Dead 1
20 STLPDC B M 18 23 Dead 0.1
21 STLPDC B M 65 52 Dead 2.2
22 favour STLPDC A3 or B M NA NA Dead 0.7
Abbreviations: NA not available, mth months, P polymorphic, M monomorphic.
Figure 5 Immunohistochemical expression of cyclin E2 protein and Ki67 proliferation rate in M-group compared to P-group cases.
Case 7 with type A2 disease and polymorphic morphology (P-group) (A, H&E original magnification 600×) showing low cyclin E2 expression
(B, CD3/cyclin E2 double stain, original magnification 600×) and low Ki67 proliferation (C, CD3/Ki67 double stain, original magnification 600×). Case 19
with type B disease and monomorphic morphology (M-group) (D, H&E original magnification 600×) with moderately high cyclin E2 expression
(E, CD3/cyclin E2 double stain, original magnification 600×) and high Ki67 proliferation (F, CD3/Ki67 double stain). CD3 stains cell membrane/
cytoplasm red, and cyclin E2 and Ki67 stain nucleus brown. All photographs were taken with a DP20 Olympus camera (Olympus, Tokyo, Japan) using
an Olympus BX41 microscope (Olympus). Images were acquired using DP Controller 2002 (Olympus) and processed using Adobe Photoshop version
5.5 (Adobe Systems, San Jose, CA, USA).
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group) had significantly shorter survival compared to P-
group cases with polymorphic infiltrate. In our study, all
but one case, with a monomorphic infiltrate had an
overall survival of less than 3 months. This highlights
the importance of morphology in predicting outcome
and that cases with frank malignant proliferation should
be regarded as an aggressive lymphoma and treated as
such. This is in line with the recommendation from the
consensus meeting in NIH 2008 that the term “CAEBV”
should not be applied to systemic LPDs that contain a
frankly malignant infiltrate, ie. Ohshima A3 and B sub-
types [12].
Recently, Quintanilla-Martinez et al. described 20 cases
of Hydroa vacciniforme–like lymphoma (HVLL), which is
also an EBV-positive T-cell lymphoproliferative disorder
of childhood but with predominant cutaneous manifesta-
tions [21]. The authors found that although HVLL in gen-
eral showed a favorable response to conservative therapy,
there is a risk to develop systemic lymphoma and criteria
such as presence of systemic symptoms, T-cell clonality,
amount of EBV-positive cells, and/or density of the in-
filtrate do not help in predicting which patients will
eventually progress to systemic disease [21]. Hence, the
challenge remains to identify morphological or clinical
markers to predict outcome or clinical progression. Im-
portantly, in this study of EBV-associated T/NK LPD
with primarily systemic presentation, our GEP data re-
vealed cyclinE2 gene to be overexpressed in M-group
compared to P-group patients. Using immunohistochem-
istry double stains, we found a corresponding higher pro-
tein expression of cyclin E2 in M-group patients and this
is associated with poor outcome, thus supporting the
validity of our GEP data. We further showed that the
upregulation of cyclinE2 in patients with poor outcome
is significantly correlated with a higher Ki67 prolifera-
tion rate.
The question of whether cyclin E2 is merely a link in
the chain of events that lead to cell proliferation or
whether it is a driving force in cell replication in TNKLPD
is difficult to ascertain at present. In some neoplasms, cyc-
lin E gene amplification and protein accumulation are late
events [22,23] whereas in other tumors an increase in cyc-
lin E is observed early in the progression to malignancy
[24,25]. Since cyclinE2 overexpression is associated with
high Ki67 proliferation, monomorphic large cell morph-
ology and poor outcome, it is tempting to speculate that
the upregulation of cyclinE2 is merely a reflection of
tumor progression in TNKLPD. However, one patient
(case 11) in this study showed polymorphic morphology
and low Ki67 proliferation, but high cyclinE2 expression.
This patient had a fairly aggressive outcome and died of
disease within 2 years of diagnosis, suggesting that
cyclinE2 upregulation in some TNKLPD may not simplybe due to proliferation and disease progression. It is also
interesting to note that, unlike cyclin E1 and Ki67 which
are expressed in most proliferating normal and tumor
cells, cyclin E2 levels are often low to undetectable in
non-transformed cells and increased significantly in
tumor-derived cells [26]. Hence, it is possible that
cycinE2 may be a more specific marker of tumor prolif-
eration than Ki67.
Conclusion
We described 22 cases of TNKLPD with systemic pres-
entation, including CAEBV of T/NK type and systemic
EBV +T cell LPD of childhood and found the presence of
a monomorphic infiltrate and high cyclin E2 and Ki-67 ex-
pression to be associated with poor outcome in TNKLPD,
which is a rare disease with no known markers of prog-
nostic significance to date. Whether cyclin E2 alone or in
combination with Ki67 and morphology allows better
prognostic stratification than standard morphology re-
quires further study with larger sample size.
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